SWAV stock continues to be an attractive investment due to its leadership in intravascular lithotripsy and its promising growth potential. The company’s acquisition by Johnson & Johnson further strengthens its prospects, positioning SWAV for long-term success in the global cardiovascular market. While the stock is expected to maintain strong growth in 2026, investors should consider the dynamic factors influencing its performance, including regulatory approvals, market sentiment, clinical adoption, and insights from platforms like Goattank.
Shockwave Medical (SWAV) Stock: Comprehensive Forecast & Price Prediction for 2026
Table of Contents
SWAV Stock Analysis: Price Forecast & Prediction for 2026
Shockwave Medical, Inc. (Ticker: SWAV) has become a leading innovator in the cardiovascular treatment space, thanks to its pioneering technology in intravascular lithotripsy (IVL). This medical device company focuses on treating calcified plaque in arteries, offering a more effective and safer alternative to traditional methods like balloon angioplasty and stenting. Since its IPO in 2019, Shockwave Medical has significantly impacted the medical device industry, with a trajectory marked by strong growth, innovation, and an acquisition by Johnson & Johnson in 2024. As of early 2026, SWAV stock remains a high-growth asset with substantial potential.
Shockwave Medical Overview
Shockwave Medical is revolutionizing the way cardiovascular diseases, such as coronary artery disease (CAD) and peripheral artery disease (PAD), are treated. The company’s IVL technology uses sonic pressure waves to break down calcium deposits in arteries, allowing for better blood flow. By providing a safer and more effective treatment for calcified lesions, Shockwave is addressing a critical unmet need in the cardiovascular field.
Shockwave Medical is transforming cardiovascular care with its innovative IVL technology, providing a safer and more effective solution for treating calcified lesions and improving blood flow in patients with coronary and peripheral artery diseases
The company has expanded its product portfolio, targeting both coronary and peripheral vascular diseases, and has ventured into additional cardiovascular applications, such as heart valve disease and carotid treatments. Shockwave’s IVL catheters and devices, such as the Reducer system for refractory angina, are a testament to the company’s commitment to addressing various heart health challenges.
IPO and Stock History
Since its IPO, SWAV stock has seen impressive growth, reflecting the company’s strong performance and the increasing adoption of its IVL technology. From lows around $23 per share in early 2020, SWAV has surged well past $300 by 2024, showcasing its remarkable stock performance and the significant investor interest it has garnered over the years. The company’s market capitalization reached $12–12.6 billion by early 2025, solidifying its position as a leader in the medical device sector.
Financial Performance
Before its acquisition by Johnson & Johnson, Shockwave Medical consistently posted impressive financial figures. For the trailing twelve months leading into 2025, the company reported revenue of around $787 million and net income exceeding $160 million. This solid performance, coupled with strong cash flow, demonstrated the growing demand for Shockwave’s technology. Additionally, Shockwave maintained a healthy balance sheet with over $1 billion in cash and manageable debt, signaling both financial strength and strategic flexibility.Shockwave’s success can be attributed to its strategic product development, clinical adoption, and increasing use of its IVL technology in cardiovascular procedures.
Acquisition by Johnson & Johnson
A pivotal moment for Shockwave Medical came in May 2024 when it was acquired by Johnson & Johnson for approximately $13 billion. This acquisition marked the integration of Shockwave’s IVL technology into J&J’s larger cardiovascular portfolio, positioning Shockwave for continued global growth under the MedTech division of Johnson & Johnson.As part of the broader medical device giant, Shockwave Medical benefits from enhanced resources and global market reach.
SWAV Stock Forecast for 2026
Looking ahead to 2026, SWAV stock is poised to continue its growth trajectory, bolstered by the backing of Johnson & Johnson and the continued adoption of its IVL technology. The stock’s performance will likely remain influenced by several factors, including the company’s ability to expand its product portfolio, gain FDA approvals for new applications, and maintain strong clinical evidence supporting the efficacy of its devices.
With the support of Johnson & Johnson and a growing portfolio of FDA-approved applications, Shockwave Medical’s continued innovation in heart valve disease and carotid treatments positions SWAV stock for sustained growth and long-term success
Shockwave’s focus on heart valve disease and carotid applications presents significant growth opportunities, as these segments are ripe for innovation. Additionally, increasing physician adoption of IVL and growing clinical evidence will continue to drive confidence in the stock and support its long-term growth potential.
Key Considerations for Investors
- Innovative Leadership
Shockwave Medical remains a leader in the field of intravascular lithotripsy, a breakthrough technology that offers significant advantages over traditional cardiovascular treatments. The company’s continued innovation in this space will drive its market position and stock performance. - Regulatory Approvals and Clinical Evidence
Ongoing regulatory approvals and clinical trials will play a crucial role in the future performance of SWAV stock. Positive data from clinical trials will boost investor confidence and support the stock’s price appreciation. - M&A Impact
The acquisition by Johnson & Johnson provides Shockwave with additional resources, global reach, and cross-collaboration opportunities. This integration could further enhance the company’s growth prospects, increasing the value of SWAV stock. - Market Sentiment and Healthcare Sector Trends
The broader medical device sector will influence SWAV stock performance, particularly trends related to regulatory changes, reimbursement policies, and advancements in cardiovascular treatments. SWAV’s position in the growing field of interventional cardiology will benefit from these trends.
Conclusion
FAQs
1. What is SWAV stock?
SWAV stock represents Shockwave Medical, Inc., a leading innovator in cardiovascular treatments, particularly for calcified plaque in arteries using intravascular lithotripsy.
2. How has SWAV stock performed since its IPO?
Since its IPO in 2019, SWAV stock has seen impressive growth, reaching prices well into the hundreds of dollars per share by 2024.
3. What is Shockwave Medical’s main technology?
Shockwave Medical’s primary technology is intravascular lithotripsy (IVL), a groundbreaking treatment for calcified arterial plaque.
